| scholarly article | Q13442814 |
| P50 | author | Pier-Luigi Lollini | Q37838964 |
| P2093 | author name string | Comoglio PM | |
| Basso G | |||
| Scotlandi K | |||
| Di Renzo MF | |||
| Olivero M | |||
| Ferracini R | |||
| De Giovanni C | |||
| Martano M | |||
| Nanni P | |||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phenotype | Q104053 |
| rhabdomyosarcoma | Q1898141 | ||
| P304 | page(s) | 1697-1705 | |
| P577 | publication date | 1996-04-01 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomas | |
| P478 | volume | 12 |
| Q48270323 | 89Zr-DFO-AMG102 Immuno-PET to Determine Local Hepatocyte Growth Factor Protein Levels in Tumors for Enhanced Patient Selection |
| Q38083828 | A call to ARMS: targeting thePAX3-FOXO1gene in alveolar rhabdomyosarcoma |
| Q54445050 | A new drug in thoracic oncology: MetMab (onartuzumab) |
| Q47303095 | Activated HGF-c-Met Axis in Head and Neck Cancer |
| Q33964561 | An engineered PAX3-KRAB transcriptional repressor inhibits the malignant phenotype of alveolar rhabdomyosarcoma cells harboring the endogenous PAX3-FKHR oncogene |
| Q28537996 | Analysis of molecular cytogenetic alteration in rhabdomyosarcoma by array comparative genomic hybridization |
| Q34786049 | Application of comparative genomic hybridization, spectral karyotyping, and microarray analysis in the identification of subtype-specific patterns of genomic changes in rhabdomyosarcoma |
| Q37750050 | C-MET as a new therapeutic target for the development of novel anticancer drugs |
| Q33786959 | Disassociation of met-mediated biological responses in vivo: the natural hepatocyte growth factor/scatter factor splice variant NK2 antagonizes growth but facilitates metastasis |
| Q35961109 | Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor |
| Q26741977 | Does it make sense to target one tumor cell chemotactic factor or its receptor when several chemotactic axes are involved in metastasis of the same cancer? |
| Q42282846 | Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody. |
| Q42912698 | Frzb, a secreted Wnt antagonist, decreases growth and invasiveness of fibrosarcoma cells associated with inhibition of Met signaling |
| Q36739725 | Hepatocyte Growth Factor-mediated satellite cells niche perturbation promotes development of distinct sarcoma subtypes |
| Q39381922 | Imatinib and Dasatinib Inhibit Hemangiosarcoma and Implicate PDGFR-β and Src in Tumor Growth |
| Q79269259 | Impact of c-Met expression on angiogenesis in soft tissue sarcomas: correlation to microvessel-density |
| Q73393706 | Induction of c-met proto-oncogene expression at the metastatic site |
| Q38859217 | Inhibition of ligand-independent constitutive activation of the Met oncogenic receptor by the engineered chemically-modified antibody DN30. |
| Q33901521 | Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274 |
| Q37653512 | Initial testing (Stage 1) of TAK-701, a humanized hepatocyte growth factor binding antibody, by the Pediatric Preclinical Testing Program. |
| Q34584035 | Invasive growth: from development to metastasis |
| Q38833050 | Liposarcoma: molecular targets and therapeutic implications |
| Q35832923 | MET receptor is a potential therapeutic target in high grade cervical cancer |
| Q38008247 | MET: a promising anticancer therapeutic target |
| Q26852728 | Mechanisms of impaired differentiation in rhabdomyosarcoma |
| Q24648202 | MicroRNA-1/206 targets c-Met and inhibits rhabdomyosarcoma development |
| Q33772210 | NK1, a Natural Splice Variant of Hepatocyte Growth Factor/Scatter Factor, Is a Partial Agonist In Vivo |
| Q42279434 | Overexpression of the hepatocyte growth factor (HGF) receptor (Met) and presence of a truncated and activated intracellular HGF receptor fragment in locally aggressive/malignant human musculoskeletal tumors. |
| Q24646520 | PAX3-FOXO1 fusion gene in rhabdomyosarcoma |
| Q35886629 | Pax genes in embryogenesis and oncogenesis |
| Q37831148 | Receptor Tyrosine Kinases as Therapeutic Targets in Rhabdomyosarcoma |
| Q37973827 | Rhabdomyosarcomas: an overview on the experimental animal models. |
| Q40054166 | Role of hepatocyte growth factor/c-Met signaling in regulating urokinase plasminogen activator on invasiveness in human hepatocellular carcinoma: a potential therapeutic target |
| Q47957999 | Role of the MET/HGF receptor in proliferation and invasive behavior of osteosarcoma |
| Q50422607 | SPRY2 is a novel MET interactor that regulates metastatic potential and differentiation in rhabdomyosarcoma. |
| Q39636176 | Selective upregulation of interleukin-8 by human rhabdomyosarcomas in response to hypoxia: therapeutic implications |
| Q39385631 | Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor |
| Q24606259 | Targeting the Hepatocyte Growth Factor–cMET Axis in Cancer Therapy |
| Q64273649 | The Possible Role of Complete Loss of Myostatin in Limiting Excessive Proliferation of Muscle Cells (C2C12) via Activation of MicroRNAs |
| Q38085900 | The emerging role of MET/HGF inhibitors in oncology |
| Q35904618 | The hepatocyte growth factor receptor as a potential therapeutic target for dedifferentiated liposarcoma |
| Q50926565 | Transgenic mice expressing PAX3-FKHR have multiple defects in muscle development, including ectopic skeletal myogenesis in the developing neural tube |
| Q92715474 | c-MET expression potentially contributes to the poor prognosis of rhabdomyosarcoma |
Search more.